Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01901289 · ClinicalTrials.gov registry record · NA
Zilver® PTX® V Clinical Study
A NA study, sponsored by Cook Research Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
NCT01901289 is a NA study that has completed, run by Cook Research Incorporated. The registered enrollment target is 200 participants.
The verdict
NCT01901289, a NA study, has completed, sponsored by Cook Research Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
Study Summary
The Zilver® PTX® V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of the femoropopliteal arteries.
Interventions
- DEVICE Zilver® PTX® Drug-Eluting Peripheral Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2013-08 |
| Est. Completion | 2021-02-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01901289
The ClinicalTrials.gov registry entry for NCT01901289 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cook Research Incorporated, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zilver® PTX® Drug-Eluting Peripheral Stent is the first listed.
NCT01901289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01901289 about?
NCT01901289 is a clinical study titled "Zilver® PTX® V Clinical Study". The Zilver® PTX® V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of the femoropopliteal arteries.
What is the current status of trial NCT01901289?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2013-08. Estimated completion is 2021-02-15.
What interventions are being tested in trial NCT01901289?
The interventions under investigation include: Zilver® PTX® Drug-Eluting Peripheral Stent (DEVICE).
Who is sponsoring clinical trial NCT01901289?
This trial is sponsored by Cook Research Incorporated, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.